- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00597493
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme
PURPOSE AND OBJECTIVES:
Primary Objective To evaluate the activity of Sorafenib plus protracted, daily temozolomide in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month PFS.
Secondary Objectives To evaluate the safety and toxicity of combination therapy using Sorafenib plus temozolomide; To determine the pharmacokinetics of Sorafenib when combined with temozolomide in patients on and not on concurrent EIAC medications.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
STUDY ACTIVITIES AND POPULATION GROUP:
This is an open-label, non-randomized, single center phase 2 trial. A treatment cycle will consist of 4 weeks of therapy.
Sorafenib will be administered at a set dose of 400 mg (2 x 200 mg tablets) twice daily, without food (at least 1 hour before or 2 hours after eating). Temozolomide will be administered at a set dose of 50 mg/m2 once daily without food (at least 1 hour before or 2 hours after eating).
Thirty-two (32) patients will be enrolled in this single-stage study.
DATA ANALYSIS AND RISK/SAFETY ISSUES:
After 16 patients with recurrent GBM are treated, an interim analysis will be conducted. If 6 or more patients have experienced unacceptable toxicity, accrual of patients in this patient group will be terminated. Otherwise, patient accrual will continue. If 9 or more of the total 32 patients experience unacceptable toxicity, the treatment regimen will be considered to have an unacceptable toxicity profile. The type I and II error rates associated with this testing are 0.053 and 0.053, respectively.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Health System
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have histologically confirmed diagnosis of recurrent/progressive GBM. Recurrence will be distinguished from "pseudoprogression" following XRT/Temodar as outlined in inclusion criteria 4.6 (below). Pts with recurrent disease whose diagnostic pathology confirmed glioblastoma multiforme will not need re-biopsy. Pts with prior low-grade glioma or WHO grade III malignant glioma are eligible if histologic assessment demonstrates transformation to GBM.
- Age > 18 years.
- Pts must be presenting in 1st, 2nd or 3rd relapse. Prior therapy must have included external beam radiotherapy.
Adequate bone marrow, liver and renal function as assessed by following:
- Hemoglobin > 9.0 g/dl
- Absolute neutrophil ct (ANC) > 1,500/mm3
- Platelet ct > 100,000/mm3
- Total bilirubin < 1.5 x ULN
- ALT & AST < 2.5 x ULN ( < 5 x ULN for pts with liver involvement)
- INR < 1.5 or PT/PTT within normal limits (unless on therapeutic anti-coagulation). Pts receiving anti-coagulation treatment with agent such as warfarin or heparin may be allowed to participate. For pts on warfarin, INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by local standard of care, until INR is stable.
- Creatinine < 1.5 x ULN
- An interval of at least 2 weeks between prior surgical resection (1 week for biopsy)& initiation of study regimen;
- An interval of at least 12 weeks from completion of standard, daily XRT, unless 1 of the following occurs: 1) new area of enhancement on MRI imaging that is outside XRT field; 2) biopsy proven recurrent tumor; 3) radiographic evidence of progressive tumor on 2 consecutive scans at least 4 weeks apart.
- An interval of at least 4 weeks from prior chemotherapy (except nitrosoureas which require 6 weeks) unless there is unequivocal evidence of tumor progression and pts has recovered from all anticipated toxicities from prior therapy.
- Karnofsky performance score > 60%.
- Ability to understand and willingness to sign written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
- If sexually active, patients will take contraceptive measures (barrier method of birth control) for duration of treatments and for 3 months following discontinuation of sorafenib & temozolomide.
- Pts who have had prior bevacizumab are eligible however interval of at least 6 weeks must have elapsed since their last dose.
Exclusion Criteria:
- Prior treatment with sorafenib.
- Significant cardiac disease including any of following: a) congestive heart failure > class II NYHA; b) unstable angina (anginal symptoms at rest); c) new onset angina (within last 3 months); d) myocardial infarction within past 6 months; e) cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- Known severe hypersensitivity to sorafenib or any of excipients or temozolomide.
- Excessive risk of bleeding as defined by stroke within prior 6 months, history of CNS or intraocular bleed, or septic endocarditis.
- Female pts who are pregnant/breast feeding, or adults of reproductive potential not employing effective method of birth control.
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in study such as uncontrolled diabetes, uncontrolled hypertension, active clinically serious infection > CTCAE Grade 2, history of bleeding diathesis or coagulopathy, impairment of GI function or GI disease that may significantly alter absorption of the study regimen (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow tablets).
- Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within past 6 months
- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of 1st dose of study drug.
- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of 1st dose of study drug.
- Serious non-healing wound, ulcer, or bone fracture.
- Major surgery, open biopsy or significant traumatic injury within 4 weeks of 1st study drug.
- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- Pt is < 3 years free of another primary malignancy except: if other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is basal cell skin cancer or cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
- Pts unwilling or unable to comply with protocol including ability to swallow whole pills or presence of any malabsorption syndrome.
- Concurrent administration of St. John's Wort.
- Clinically serious infection requiring active intervention (CTCAE grade 2 or greater).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Sorafenib + Temozolomide
Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure |
Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib.
Sorafenib will be taken by mouth twice every day.
The dose of sorafenib will be 400 mg (2 x 200mg tablets).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
6 Month Progression Free Survival (PFS)
Prazo: 6 months
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause.
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Safety and Toxicity of Combination
Prazo: 16 months
|
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment.
|
16 months
|
Pharmacokinetics: C-max
Prazo: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
C-max refers to maximum plasma concentration.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately.
|
13 months
|
Pharmacokinetics: T-max
Prazo: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
T-max refers to time to maximum concentration.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately.
|
13 months
|
Pharmacokinetics: AUC-24
Prazo: 13 months
|
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose.
AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours.
The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately.
|
13 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: David A Reardon, MD, Duke Health
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias Glandulares e Epiteliais
- Atributos da doença
- Astrocitoma
- Glioma
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Glioblastoma
- Recorrência
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Agentes Antineoplásicos Alquilantes
- Agentes Alquilantes
- Inibidores de proteína quinase
- Temozolomida
- Sorafenibe
Outros números de identificação do estudo
- Pro00000464
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Glioblastoma Multiforme Recorrente
-
University Hospital MuensterIsotope Technologies Munich (ITM) Oncologics; Helmholtz Zentrum München Deutsches...RecrutamentoGlioblastom OMS Grau 4Alemanha
Ensaios clínicos em Sorafenib and Temozolomide
-
BayerConcluídoCarcinoma hepatocelularTaiwan
-
University Hospitals Cleveland Medical CenterDesconhecidoAsma | Rinite alérgica | Conjuntivite alérgicaEstados Unidos
-
John SappNova Scotia Health Authority; Rochester Institute of TechnologyRecrutamentoInfarto do miocárdio | Taquicardia ventricularCanadá
-
hearX GroupUniversity of PretoriaConcluído
-
GlaxoSmithKlineConcluídoTétano | Difteria | Coqueluche AcelularEstados Unidos
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecrutamentoDemência | Comprometimento cognitivo leve | Demência, Mista | Demência do Tipo Alzheimer | Comprometimento Cognitivo Subjetivo | Demência senilSuécia
-
University of South CarolinaAtivo, não recrutandoCompulsão Alimentar | Imagem corporal | Comportamento Alimentar | Nutrição, Saudável | Comer TranstornadoEstados Unidos
-
National University of MalaysiaConcluídoAplicações MóveisMalásia
-
Institut du Cancer de Montpellier - Val d'AurelleUniversity Hospital, Clermont-Ferrand; Laboratoire EPSYLON; Academic resource...Concluído
-
Eunice Kennedy Shriver National Institute of Child...Desconhecido